POLARIS: A Phase 1, Single Dose, Open-label Study of GNTI-122 in Adults With Recently Diagnosed Type 1 Diabetes (T1D)
Latest Information Update: 10 Oct 2025
At a glance
- Drugs GNT I122 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms POLARIS
- Sponsors GentiBio
Most Recent Events
- 22 Sep 2025 Status changed from not yet recruiting to recruiting.
- 11 Apr 2025 Status changed from planning to not yet recruiting.
- 07 Oct 2024 New trial record